- For in vitro testing and laboratory use only.
- Not for human or animal consumption.
- Bodily introduction is illegal.
- Handle only by licensed professionals.
- Not a drug, food, or cosmetic.
- Educational use only.
Quick take on 5-Amino-1MQ
5-Amino-1MQ (5-amino-1-methylquinolinium) is a small synthetic molecule, not a peptide — worth noting upfront because it's often lumped into peptide discussions despite being structurally unrelated. It was developed as a research chemical by scientists studying NNMT (nicotinamide N-methyltransferase), an enzyme that has become a hot target in obesity and metabolic disease research. Published research began appearing around 2018, with the molecule emerging from Alessandro Doria's lab at the Joslin Diabetes Center. It's available as a research chemical, typically in oral capsule form.
Mechanism in plain English
5-Amino-1MQ is a selective NNMT inhibitor. NNMT is overexpressed in the fat tissue and muscle of obese individuals, where it wastes methyl groups and nicotinamide (a NAD+ precursor), disrupting cellular energy metabolism. By inhibiting NNMT, the compound appears to increase cellular NAD+ levels, boost energy expenditure in fat cells, reduce fat accumulation, and enhance muscle function. In obese mouse models, NNMT inhibition produced reduced body weight, improved insulin sensitivity, and protection against diet-induced obesity.
What it's used for
People take it for fat loss without appetite suppression, metabolic optimization, and muscle preservation during caloric restriction. The appeal is specifically that it doesn't work like GLP-1 drugs — it doesn't suppress hunger, doesn't cause GI distress, and theoretically targets the metabolic machinery of fat cells directly. Effects are gradual, typically appearing over 4-8 weeks of consistent use, with modest fat loss and subjective reports of improved energy.
Upsides and downsides
Main upside — a genuinely novel mechanism targeting an enzyme that appears legitimately important in obesity biology, with animal data supporting the theory and no major safety signals identified in preclinical work. For people who can't tolerate GLP-1 drugs or want to avoid appetite-based mechanisms, 5-Amino-1MQ offers a different angle on metabolic intervention.
Main downside — the evidence in humans is essentially zero. Everything we know comes from cell cultures and mouse studies. No controlled human trials have been published, no pharmacokinetic data in people exists, and real-world results reported by users range from "significant recomposition" to "felt nothing at all."
Typical protocol
Protocols run 50-150 mg orally once daily, often taken in the morning with food, in cycles of 8-12 weeks with breaks. Oral bioavailability is presumed adequate based on the molecule's size and structure, but has not been formally characterized in humans.
Who should skip it
- Pregnant or breastfeeding women.
- Anyone with active liver or kidney disease.
- Anyone on methylation-sensitive medications — NNMT inhibition affects methyl group metabolism systemically.
Regulatory status
Not on WADA's prohibited list. Not approved as a medication anywhere; sold strictly as a research chemical.
In 2014, a research team led by Jamey Marth published a paper in Nature Medicine that went largely unnoticed outside metabolic research circles. They'd identified an enzyme that showed up in the fat tissue of obese people and mice — an enzyme nobody had connected to obesity before. When they blocked this enzyme in mice on high-fat diets, the mice lost weight. Without eating less. Without changing activity levels. Just from turning off this single enzyme.
The enzyme was nicotinamide N-methyltransferase (NNMT). And the paper planted the seed of an idea that would animate obesity research for the next decade: what if a significant portion of fat storage and metabolic slowdown was regulated by a single enzymatic switch? [1]
Four years later, in 2018, Sweidan Neelakantan and colleagues at Yeshiva University designed the first potent small-molecule inhibitor of NNMT. Their compound was called 5-Amino-1-methylquinolinium — 5-Amino-1MQ for short. Tested in diet-induced obese mice, it reduced body weight, shrunk white adipose tissue, and decreased adipocyte size — again, without affecting appetite [2].
5-Amino-1MQ has become one of the most discussed compounds in biohacker, longevity, and metabolic health communities. Important to understand upfront: it is not a peptide. It's a small-molecule drug. It's also entirely preclinical — no human clinical trials have been conducted. Everything known about it comes from mouse models, cell culture experiments, and mechanistic research. What we cover below reflects that preclinical evidence base with the appropriate caveats.
5-Amino-1MQ: what it is and how it works in a nutshell
5-Amino-1MQ is a small-molecule compound — specifically 5-amino-1-methylquinolinium. Chemically, it's a methylquinolinium derivative, not a peptide. This distinction matters:
- Not a peptide (despite being marketed alongside peptides)
- Small molecule — orally bioavailable, membrane-permeable
- Synthetic drug designed as a research tool
- Selective inhibitor of NNMT — the defining mechanism
Origin: designed and first characterized by Neelakantan et al. (2018) at Albert Einstein College of Medicine/Yeshiva University, building on earlier NNMT biology from the Marth lab [2].
Regulatory status:
- Not FDA-approved for any indication
- No human clinical trials have been conducted or published
- Sold through research peptide/compound suppliers and some compounding pharmacies
- Purely experimental research compound in terms of evidence base
This is crucial framing. Unlike most compounds covered on this blog, 5-Amino-1MQ has not been tested in humans at all. Every claim about its effects in people is extrapolation from mouse data, which has a notorious track record for not translating to humans.
5-Amino-1MQ mechanism of action: what it actually does
Understanding 5-Amino-1MQ requires understanding NNMT, the enzyme it inhibits.
What NNMT does:
NNMT catalyzes a specific chemical reaction — it transfers a methyl group from S-adenosyl-L-methionine (SAM) to nicotinamide (vitamin B3), producing 1-methyl nicotinamide (1-MNA) as a waste product [3]. This single enzymatic action has two downstream consequences:
- Depletes SAM — the body's main methyl donor, used throughout the genome for DNA methylation and epigenetic regulation
- Depletes nicotinamide — the precursor for NAD+ (nicotinamide adenine dinucleotide), the most important cellular energy metabolism cofactor
When NNMT is overactive (as it is in obese fat tissue), both SAM and nicotinamide get drained, which in turn reduces NAD+ levels (slowing mitochondrial energy production), dysregulates methylation patterns (altering gene expression toward fat storage), and activates signaling that promotes adiposity.
What 5-Amino-1MQ does:
Blocks NNMT enzymatic activity, preventing the depletion of both SAM and nicotinamide. The downstream effects:
- Preserved NAD+ levels — mitochondrial energy metabolism functions normally
- Preserved SAM levels — methylation balance maintained
- SIRT1 activation — the "longevity sirtuin" that requires NAD+
- Increased energy expenditure — basal metabolic rate rises
- Enhanced fat oxidation — fat cells shift from storage to burning
- Reduced fat cell size — adipocytes physically shrink
The Kraus 2014 Nature Medicine findings: in diet-induced obese mice, NNMT knockdown produced protection from weight gain despite continued high-fat diet, reduced adipose tissue mass, improved insulin sensitivity — and no effect on food intake. The mice ate the same amount. This last point is critical. Most weight-loss interventions work through reducing intake. NNMT inhibition appears to work through increasing expenditure — a fundamentally different approach [1].
The muscle angle. NNMT inhibitors have also been investigated for muscle stem cell (satellite cell) activation. Published research shows that NNMT inhibition enhances muscle satellite cell proliferation and fusion, producing larger muscle fibers and improved contractile strength — particularly in aged organisms where satellite cells have become less responsive [4]. This has generated interest in NNMT inhibition for sarcopenia (age-related muscle loss).
Pharmacokinetics: orally bioavailable (unlike peptides, which are destroyed in the GI tract), reasonable membrane permeability, estimated half-life allows for once or twice daily oral dosing based on preclinical data. No human PK data exists.
Who uses 5-Amino-1MQ and what for
This section reflects reality honestly: 5-Amino-1MQ use is almost entirely speculative, based on mouse data and biohacker enthusiasm rather than clinical evidence.
- Biohackers and longevity-focused individuals — the largest user group. Attracted by the NAD+ preservation angle and the "novel mechanism" framing.
- People seeking weight loss who've tried other approaches — attracted by the "loses weight without changing appetite" mouse data.
- Bodybuilders during cutting phases — attracted by the theoretical muscle-preservation angle.
- Aging adults concerned about sarcopenia — attracted by the satellite cell activation research.
- Researchers studying NNMT biology — the legitimate scientific user group. 5-Amino-1MQ is a valid research tool for probing NNMT pathways in cell culture and animal models.
In mouse models, 5-Amino-1MQ produced reduced body weight and adipose tissue, improved insulin sensitivity, enhanced muscle satellite cell activation, and no significant adverse effects in short-term studies.
In humans: unknown. No human trials have been published.
What we specifically don't know about 5-Amino-1MQ in humans: whether oral bioavailability is adequate at safe doses; whether mouse-observed effects translate to human metabolism; what effective doses would be; what the safety profile looks like; long-term effects on NAD+/methylation homeostasis; cancer implications of chronic NNMT inhibition.
What WON'T happen (even in optimistic projections): dramatic weight loss comparable to semaglutide or tirzepatide (those are proven in humans; 5-Amino-1MQ isn't); immediate or noticeable effects (the mechanism works through gradual metabolic shifts); substitution for proven interventions in anyone with significant metabolic disease.
What 5-Amino-1MQ stacks with: theoretical considerations
Formal research on stacking doesn't exist. Based on mechanism:
- 5-Amino-1MQ + NAD+ precursors (NMN, NR) — theoretically synergistic, both support the NAD+ salvage pathway
- 5-Amino-1MQ + Resistance training + adequate protein — if the satellite cell data translates, the mechanism requires mechanical stimulus to produce muscle benefits
- 5-Amino-1MQ + Metformin — different mechanisms, theoretically complementary for metabolic health
- 5-Amino-1MQ + GLP-1 agonists — completely different mechanisms, theoretically complementary (appetite reduction from GLP-1 + energy expenditure increase from 5-Amino-1MQ)
Nothing stated above has been validated in human trials.
5-Amino-1MQ side effects and risks
The honest answer: we don't have human safety data. Everything below is either preclinical observation or theoretical concern.
In mouse studies (short-term): no significant adverse effects reported; no changes in food intake; no observable behavioral changes; no overt toxicity at effective doses.
Theoretical concerns worth taking seriously:
- Methylation pathway disruption — NNMT affects SAM metabolism, which affects DNA methylation and epigenetic regulation. Long-term inhibition could have unanticipated effects on gene expression patterns.
- Cancer biology concerns — NNMT is highly expressed in many cancers. Some research suggests NNMT activity promotes cancer progression; some suggests the opposite in specific contexts. Chronic inhibition in humans has unknown cancer implications.
- NAD+ redistribution effects — while raising NAD+ seems beneficial, the downstream effects of chronically elevated NAD+ through NNMT inhibition haven't been characterized in humans.
- Quality control of research-grade material — 5-Amino-1MQ sold online varies in purity, exact compound identity, and contaminants. Research chemical sources have no manufacturing quality standards comparable to pharmaceuticals.
Who should absolutely avoid:
- Anyone with active or recent history of cancer (theoretical NNMT-cancer concerns)
- Pregnant or breastfeeding women
- Children
- People with significant liver disease (liver is NNMT-rich)
- Anyone expecting this to be a proven intervention rather than a research experiment
- People with active autoimmune disease (methylation effects unclear)
The broader risk framing: using a preclinical compound on yourself is categorically different from using an FDA-approved medication off-label. The latter has been validated in humans for some indication; the former has never been validated in humans for anything.
How 5-Amino-1MQ is typically used
Oral administration — unlike peptides, 5-Amino-1MQ is orally bioavailable as a small molecule.
Common off-label protocols (not clinically validated):
- Dose: 50-150 mg once daily, typically taken in the morning
- Cycle: 8-12 weeks on, 2-4 weeks off is common in biohacker protocols
- Timing: morning with food is the typical recommendation, based on practical considerations rather than clinical pharmacokinetic data
Storage: solid powder, stable at room temperature but refrigeration extends shelf life. Once dissolved for administration, stability varies by vehicle.
5-Amino-1MQ vs alternatives: what's different
- GLP-1 agonists (Semaglutide, Tirzepatide) — proven clinical interventions for weight loss with dramatic efficacy and extensive safety data. Different mechanism (appetite suppression vs energy expenditure). If you want weight loss with validated evidence, these win decisively.
- NAD+ precursors (NMN, NR) — increase NAD+ through supply rather than NNMT inhibition. Oral supplements with broader human experience, limited clinical evidence for dramatic effects. Complementary mechanism theoretically.
- Metformin — established insulin sensitizer with decades of clinical use. Different mechanism but overlapping metabolic effects. Cheap, proven, prescription-available.
- Berberine — plant-derived metabolic modulator with some clinical evidence. Oral, cheap, widely available as supplement.
5-Amino-1MQ's distinguishing feature: the most-developed small-molecule NNMT inhibitor with a novel mechanism (energy expenditure increase through enzyme inhibition) — but entirely preclinical, with no human trial data validating the approach.
Myths about 5-Amino-1MQ
- "5-Amino-1MQ is a peptide that boosts metabolism." It's not a peptide. It's a small-molecule drug (5-amino-1-methylquinolinium). Being frequently sold alongside peptides on research chemical sites doesn't make it a peptide. This matters for understanding its pharmacology, administration, and regulatory status.
- "Mouse studies prove 5-Amino-1MQ works for human weight loss." Mouse studies demonstrate the mechanism and show promising preclinical results. They do not prove efficacy in humans. Roughly 90% of drugs that work in mouse models fail in human clinical trials. The path from mouse data to validated human treatment requires years of controlled clinical trials that haven't been done for 5-Amino-1MQ.
Sources
- Kraus, D., Yang, Q., Kong, D., Banks, A. S., Zhang, L., Rodgers, J. T., Pirinen, E., Pulinilkunnil, T. C., Gong, F., Wang, Y. C., Cen, Y., Sauve, A. A., Asara, J. M., Peroni, O. D., Monia, B. P., Bhanot, S., Alhonen, L., Puigserver, P., & Kahn, B. B. (2014). Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature, 508(7495), 258-262. https://pubmed.ncbi.nlm.nih.gov/24717514/ — the foundational paper establishing NNMT as an obesity target.
- Neelakantan, H., Vance, V., Wetzel, M. D., Wang, H. L., McHardy, S. F., Finnerty, C. C., Hommel, J. D., & Watowich, S. J. (2018). Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochemical Pharmacology, 147, 141-152. — the paper introducing 5-Amino-1MQ as a selective NNMT inhibitor with in vivo obesity data.
- Pissios, P. (2017). Nicotinamide N-methyltransferase: More than a vitamin B3 clearance enzyme. Trends in Endocrinology & Metabolism, 28(5), 340-353. — comprehensive review of NNMT biology and its metabolic roles.
- Neelakantan, H., Brightwell, C. R., Graber, T. G., Maroto, R., Wang, H. L., McHardy, S. F., Papaconstantinou, J., Fry, C. S., & Watowich, S. J. (2019). Small molecule nicotinamide N-methyltransferase inhibitor activates muscle stem cells and improves strength in aging. Biochemical Pharmacology, 163, 481-492. — key paper on NNMT inhibition for muscle satellite cell activation and age-related muscle function.
- Komatsu, M., Kanda, T., Urai, H., Kurokochi, A., Kitahama, R., Shigaki, S., Ono, T., Yukioka, H., Hasegawa, K., Tokuyama, H., Kawabe, H., Wakino, S., & Itoh, H. (2018). NNMT activation can contribute to the development of fatty liver disease by modulating the NAD+ metabolism. Scientific Reports, 8, 8637. — establishes NNMT's role in fatty liver disease, relevant to 5-Amino-1MQ's therapeutic rationale.
- Roberti, A., Fernández, A. F., & Fraga, M. F. (2021). Nicotinamide N-methyltransferase: At the crossroads between cellular metabolism and epigenetic regulation. Molecular Metabolism, 45, 101165. https://pmc.ncbi.nlm.nih.gov/articles/PMC8337113/ — review of NNMT at the intersection of metabolism and epigenetics, relevant to concerns about chronic NNMT inhibition.
- Ulanovskaya, O. A., Zuhl, A. M., & Cravatt, B. F. (2013). NNMT promotes epigenetic remodeling in cancer by creating a metabolic methylation sink. Nature Chemical Biology, 9(5), 300-306. — establishes NNMT as a metabolic methylation sink, relevant to understanding the broader biological implications of NNMT inhibition.
- Dimet-Wiley, A. L., Latham, C. M., Brightwell, C. R., Neelakantan, H., Graber, T. G., Reid, J. J., Miller, B. F., Fry, C. S., Hernandez, A. R., Watowich, S. J., & Peelor, F. F. (2022). Nicotinamide N-methyltransferase inhibition mimics and boosts exercise-mediated improvements in muscle function in aged mice. Scientific Reports, 12, 22469. — documents muscle functional improvements with NNMT inhibition in aged mice.
5-Amino-1MQ Dosage Guide
5-Amino-1MQ (5-amino-1-methylquinolinium) is not a peptide — it's a synthetic small molecule (~159 Da) that selectively inhibits Nicotinamide N-methyltransferase (NNMT), an enzyme highly expressed in white adipose tissue that methylates nicotinamide using SAM (S-adenosylmethionine). Overactive NNMT depletes NAD+ and SAM, promoting adipogenesis and blunting mitochondrial function. By inhibiting NNMT, 5-Amino-1MQ preserves NAD+ and SAM, activates SIRT1, and in preclinical studies reduced adipocyte size by 30–40% and decreased visceral fat without changes in food intake. This guide is aimed at users pursuing stubborn and visceral fat reduction, those stacking it with GLP-1 agonists to preserve metabolic rate during weight loss, and users exploring NAD+ and mitochondrial optimization. Dosing below combines the Neelakantan et al. (2018, 2019) preclinical studies, allometric scaling to human equivalents, and the parallel oral vs. subcutaneous community protocols that have emerged since no human clinical trials have been published.
Real-World Dosage Protocols by Experience Level
| Experience Level | Dose | Frequency | Notes |
|---|---|---|---|
| Oral starter | 50 mg | Once daily AM, oral | First 1–2 weeks to assess tolerance |
| Oral standard | 100 mg | Once daily AM, oral | Most common community maintenance dose |
| Oral upper range | 150 mg | Split AM + before 2 PM, oral | Never dose after 2 PM to avoid insomnia |
| SC starter | 2.5 mg | Once daily AM, SC | Alternative injectable route |
| SC standard | 5 mg | Once daily or split 2.5 mg BID, SC | Community injectable maintenance |
| Preclinical reference (mice) | 20 mg/kg x3/day | Three SC injections daily | Neelakantan 2018 DIO model; not for human scaling |
Doses also shift depending on the specific goal. The same molecule used for targeted fat loss versus NAD+ optimization and longevity follows similar dosing but different stacking frameworks.
Dosage by Goal
| Goal | Recommended Dose | Frequency | Cycle Length |
|---|---|---|---|
| Fat loss (visceral / stubborn fat) | 100–150 mg | Once daily AM, oral | 8–12 weeks on / 4–8 weeks off |
| General metabolic optimization | 50–100 mg | Once daily AM, oral | 8 weeks on / 4 weeks off |
| NAD+ / longevity focus | 50–100 mg | Once daily AM, oral | 8 weeks on / 4 weeks off |
| Muscle preservation on GLP-1 / caloric deficit | 100 mg + GLP-1 agonist | Once daily AM, oral | Aligned with GLP-1 cycle |
| Stacked with MOTS-c | 100 mg + 5–10 mg MOTS-c | Daily oral + 3x weekly SC MOTS-c | 8–12 weeks |
| Injectable route (community) | 5 mg | Once daily or 2.5 mg BID, SC | 8–12 weeks on / 4 weeks off |
Oral is the route supported by the existing research — 5-Amino-1MQ was designed with high Caco-2 passive and active transport and was dosed orally in most preclinical work, unlike injectable peptides. Take on an empty stomach or with a light meal in the morning; fatty meals may slow absorption, and dosing past early afternoon commonly causes insomnia because the compound increases thermogenesis and energy output. Critically, do not inject the contents of oral capsules — capsules contain fillers, binders, and excipients not formulated for subcutaneous use, so if pursuing the injectable route, use a dedicated lyophilized 5-Amino-1MQ vial designed for reconstitution. Cycle 8–12 weeks on followed by 4–8 weeks off; no human long-term safety data exists, so this cycling approach is a precaution against unknown chronic effects on methylation. Absolute contraindications include pregnancy, breastfeeding, pediatric use, active cancer, liver disease, and concurrent MAOIs or serotonergic compounds (theoretical SAM-methylation interaction). Monitor ALT and AST at baseline and every 4–8 weeks, track resting heart rate for thermogenesis, and expect measurable body composition changes at 6–12 weeks rather than days.
5-Amino-1MQ Storage Guide: How to Keep Your Research Compound Stable and Effective
5-Amino-1MQ ships as a white to off-white lyophilized powder in a sealed glass vial. As a small-molecule NNMT inhibitor (not a peptide), it's more chemically robust than most research peptides — but cold, dark, dry storage still protects it from light-induced degradation and moisture uptake. Here's exactly how to store it.
Lyophilized Powder (Unreconstituted)
| Parameter | Details | Notes |
|---|---|---|
| Storage Temperature | Freezer at −20°C (−4°F) for long-term storage up to 24 months. Refrigeration at 2–8°C (36–46°F) is fine for short-term use up to ~3 months. | Original sealed vial in the freezer is the safest default. |
| Light Sensitivity | Yes — the aromatic quinolinium structure can undergo photodegradation under UV or bright light. | Always keep in the original box or an opaque, amber container. |
| Freezing | Allowed and recommended. −20°C is standard for long-term storage; −80°C extends stability further if available. | Freeze from the start if you won't use it within 3 months. |
| Signs of Degradation | Healthy powder is white to off-white and loose or crystalline. Watch for yellowing, browning, darkening, clumping, visible moisture, or a sticky texture. | Any color change beyond light off-white, clumping, or moisture = discard the vial. |
| Common Mistakes | Leaving the vial at room temperature after delivery, storing in a humid kitchen or bathroom, or opening a cold vial and letting condensation form inside. | Put it in the freezer on arrival, and let sealed vials warm to room temperature before opening. |
Shipping & Product Authenticity
Every order is processed quickly and shipped with full tracking. All products come directly from the official Generic Peptides supply chain — in original manufacturer packaging, carefully handled from warehouse to your door.
Shipping Times
| Destination | Delivery Time | Notes |
|---|---|---|
| USA Domestic | 4–5 business days | Faster when local warehouse stock is selected at checkout |
| International | 13–15 business days | Tracking included; update frequency may vary by destination country |
| Order Processing | 24–48 business hours | Processing begins after payment confirmation |
| Tracking | Provided on all orders | Tracking number sent after dispatch; multiple warehouses may result in separate shipments |
Direct Supply & Secure Delivery
This product is supplied through the official Generic Peptides distribution chain and shipped in original manufacturer packaging. Orders are packed securely to protect the contents during transit and to respect customer privacy as a standard practice.
Outer packaging is neutral and does not display product details on the exterior — a common approach to protect shipments from damage, tampering, and unnecessary exposure during delivery.
What to Expect
- Orders are processed after payment confirmation
- USA domestic shipping is typically faster when local stock is selected
- International orders include tracking, though update frequency may vary by destination
- Multiple warehouses may result in separate shipments when applicable
Authenticity & Verified Supply
Every order includes full authenticity assurance: official Generic Peptides presentation, batch-linked lab documentation, and sealed original packaging — giving customers confidence in every purchase.
| Authenticity Feature | Details |
|---|---|
| Packaging | Original manufacturer packaging — sealed and unaltered |
| Lab Documentation | Batch-linked certificate of analysis available on request |
| Supply Chain | Sourced exclusively through official Generic Peptides distribution |
Shipping & Returns
5-Amino 1MQ (short for 5-amino-1-methylquinolinium) is a small-molecule compound — not actually a peptide, despite often being sold under that label — that acts as a selective inhibitor of the enzyme nicotinamide N-methyltransferase (NNMT). It was developed by researchers at the University of Texas Medical Branch as a potential treatment for obesity and metabolic syndrome. Unlike most research compounds in this space, 5-Amino 1MQ is orally bioavailable (taken as a capsule rather than injected), which has made it popular with users looking for a needle-free metabolic enhancer. It is not FDA-approved and has not entered human clinical trials — all published research is in cell culture and animal models.
5-Amino 1MQ works by inhibiting NNMT, an enzyme that is overactive in fat tissue of obese individuals. NNMT consumes two valuable cellular resources — NAD+ (needed for mitochondrial energy production) and SAM (a key methyl donor) — and produces 1-MNA as a waste product. When NNMT is overactive, it drains NAD+ levels, slows the metabolism, and promotes fat storage. By blocking NNMT, 5-Amino 1MQ preserves intracellular NAD+, which in turn activates sirtuin proteins (including SIRT1), boosts mitochondrial function, and shifts cellular energy balance toward fat burning rather than fat storage.
Preclinical research suggests several potential benefits: reduced body fat (especially visceral and stubborn abdominal fat), increased resting energy expenditure, improved insulin sensitivity, preservation of lean muscle mass during weight loss, and potential activation of muscle stem cells in aged tissue. In a key mouse study, obese mice treated with 5-Amino 1MQ showed roughly a 35% reduction in fat mass and 30% smaller fat cells — without any change in food intake. Important caveat: virtually all evidence comes from rodent studies and cell culture. There are no published human clinical trials, so real-world benefits in people are based on anecdote and extrapolation.
Common user protocols use 50 to 150 mg taken orally once daily, typically in the morning with food. Wellness clinics often start patients at 50 mg daily and titrate up based on tolerance and response. Cycles typically run 8 to 12 weeks, followed by a break of 4–8 weeks to avoid receptor adaptation and allow cellular systems to reset. These doses come from user protocols and compounding pharmacies — not from regulated clinical trials. The mouse studies used injectable dosing of roughly 20 mg/kg, which does not translate directly to oral human dosing.
In animal studies, 5-Amino 1MQ has shown a remarkably clean safety profile — no observable adverse effects at therapeutic doses, no weight loss from appetite suppression (animals ate the same amount), and no apparent organ toxicity. User-reported side effects are generally mild and include occasional insomnia if taken too late in the day, mild headaches, gastrointestinal discomfort, and fatigue during the first week. Because it acts through NAD+ and methylation pathways, theoretical concerns include impacts on long-term methylation balance. Long-term human safety data simply does not exist, and this is the most important limitation to keep in mind.
They work through completely different mechanisms. GLP-1 drugs (Ozempic, Wegovy) and GLP-1/GIP drugs (Mounjaro, Zepbound) work primarily by suppressing appetite and slowing digestion — you eat less, so you lose weight. 5-Amino 1MQ doesn't suppress appetite at all; it works at the cellular level to increase metabolic efficiency and shift fat cells from storage mode to burning mode. GLP-1 drugs are clinically proven with dramatic human data; 5-Amino 1MQ is preclinical with only animal evidence. Some users stack them, using 5-Amino 1MQ to help preserve muscle mass and target stubborn fat during a GLP-1 cycle.
This is one of the more interesting findings in the preclinical literature. In animal studies, 5-Amino 1MQ inhibits NNMT in skeletal muscle, which appears to activate muscle stem cells (satellite cells) and support muscle regeneration, particularly in aged animals where these cells have become sluggish. For people in a caloric deficit or on GLP-1 weight-loss drugs — both of which commonly cause muscle loss — this muscle-sparing effect is theoretically attractive. In practice, the human evidence for this benefit is absent, so claims of "muscle preservation while losing fat" remain hopeful extrapolations from mouse studies.
5-Amino 1MQ is not FDA-approved and is not available as a prescription medication. It is sold legally as a "research chemical" labeled "not for human consumption" by various peptide and research supply companies, and some wellness and anti-aging clinics offer it off-label through compounding pharmacies. Possession for personal use exists in a legal grey zone that varies by country. It is not on the WADA prohibited list as of this writing, but competitive athletes should always verify current status. Quality from unregulated vendors varies significantly, and third-party testing is essential.
Users typically report early changes — slightly improved energy, better workout performance, or more stable blood sugar — within the first 1–2 weeks. Visible changes in body composition, particularly reduction in stubborn abdominal fat, generally emerge over 6–12 weeks of consistent use combined with a reasonable diet and exercise program. Because it works by optimizing cellular metabolism rather than forcing a change, results tend to be gradual and cumulative. Users expecting dramatic GLP-1-style weight loss are usually disappointed — 5-Amino 1MQ's effects are more subtle and work best when paired with lifestyle factors.
Because human safety data is lacking, 5-Amino 1MQ should be avoided during pregnancy and breastfeeding, by anyone under 18, and by people with serious chronic health conditions unless supervised by a clinician. People taking medications that influence methylation (such as certain psychiatric drugs or methylfolate supplements) should use caution, since NNMT inhibition affects methyl group availability. Anyone with active cancer should consult an oncologist before starting, as NAD+ and sirtuin modulation can have complex effects on cell biology. Finally, it should not be used as a substitute for proven treatments for obesity or metabolic disease.
